IDIOPATHIC PULMONARY FIBROSIS (IPF)

This study tests whether taking quercetin, a natural compound found in foods like apples and onions, can slow lung scarring and improve breathing in people with pulmonary fibrosis. About 100 adults with this chronic lung disease will either receive quercetin pills plus their usua…

This study tests an experimental drug called SB17170 in 30 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The goal is to see if the drug can improve lung function compared to a placebo over 12 weeks. Participants will …

This study tests an oral medication called INS018_055 in 40 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The main goal is to check the drug's safety over 12 weeks. Participants will be randomly assigned to receive …

This study tests a new tablet called HEC585 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 472 adults aged 40 to 80 will take either HEC585, a placebo, or an existing drug (pirfenidone) for 52 weeks. The ma…

This study tests an inhaled version of the drug nintedanib (AP02) in 160 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants will inhale the drug or a placebo twice daily for 12 weeks. The goal is to see if it improves lung function and is safe.…

This study tests a new drug, SV001, in 48 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either SV001 or a placeb…

This study tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. The goal is to see if LTI-03 is safe and can protect lung cells, reduce scarring, and improve breathing compared to a placeb…

This study looks at the long-term safety of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). Participants must have completed a prior Avalyn Pharma study of the same drug. Researchers will monitor side effects and lung function over time to se…

This study tests a new drug called TDI01 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 508 adults in China will receive either TDI01 or a placebo to see if the drug helps preserve lung function over 24 to …

This study tests a new way to organize follow-up care for people with interstitial lung disease (ILD). Instead of making several separate trips for tests, lab work, and doctor visits, the new approach bundles everything into one coordinated hospital visit. The goal is to reduce t…

This early-stage study tests an inhaled form of nintedanib (MNKD-201) in 24 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check safety and how the body handles the drug, not to treat the disease. Participants will receive either the…

This study looks at lung CT scans from 500 adults with rheumatoid arthritis to better understand a serious lung complication called interstitial lung disease. Researchers want to find patterns that are unique to rheumatoid arthritis compared to other diseases. The goal is to impr…

This study tests whether bundling key tests (like CT scans and lung function tests) into a single, fast-tracked appointment can help people with suspected interstitial lung disease get a diagnosis sooner. About 92 adults will be randomly assigned to either the usual step-by-step …

This study looks at how anti-fibrotic medications affect body composition in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Researchers will use simple, non-invasive tools like bioelectrical impedance analysis (BIA) and muscle ultrasound …

This study collects blood, airway, and urine samples from up to 2,000 healthy volunteers and people with lung diseases like COPD and pulmonary fibrosis. The goal is to establish normal ranges and understand the genetic changes that lead to lung disease. Participants must be 18 or…